10-89223823-A-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting
The NM_000235.4(LIPA):āc.683T>Cā(p.Phe228Ser) variant causes a missense change. The variant allele was found at a frequency of 0.000126 in 1,614,116 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.00065 ( 0 hom., cov: 32)
Exomes š: 0.000072 ( 0 hom. )
Consequence
LIPA
NM_000235.4 missense
NM_000235.4 missense
Scores
4
7
8
Clinical Significance
Conservation
PhyloP100: 6.50
Genes affected
LIPA (HGNC:6617): (lipase A, lysosomal acid type) This gene encodes lipase A, the lysosomal acid lipase (also known as cholesterol ester hydrolase). This enzyme functions in the lysosome to catalyze the hydrolysis of cholesteryl esters and triglycerides. Mutations in this gene can result in Wolman disease and cholesteryl ester storage disease. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jan 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.021826178).
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00065 (99/152296) while in subpopulation AFR AF= 0.00214 (89/41558). AF 95% confidence interval is 0.00178. There are 0 homozygotes in gnomad4. There are 52 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LIPA | NM_000235.4 | c.683T>C | p.Phe228Ser | missense_variant | 7/10 | ENST00000336233.10 | NP_000226.2 | |
LIPA | NM_001127605.3 | c.683T>C | p.Phe228Ser | missense_variant | 7/10 | NP_001121077.1 | ||
LIPA | NM_001288979.2 | c.335T>C | p.Phe112Ser | missense_variant | 5/8 | NP_001275908.1 | ||
LIPA | XM_024448023.2 | c.683T>C | p.Phe228Ser | missense_variant | 7/10 | XP_024303791.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LIPA | ENST00000336233.10 | c.683T>C | p.Phe228Ser | missense_variant | 7/10 | 1 | NM_000235.4 | ENSP00000337354.5 | ||
LIPA | ENST00000428800.5 | c.683T>C | p.Phe228Ser | missense_variant | 6/7 | 1 | ENSP00000388415.1 | |||
LIPA | ENST00000371837.5 | c.515T>C | p.Phe172Ser | missense_variant | 6/9 | 2 | ENSP00000360903.1 | |||
LIPA | ENST00000456827.5 | c.335T>C | p.Phe112Ser | missense_variant | 5/8 | 3 | ENSP00000413019.2 |
Frequencies
GnomAD3 genomes AF: 0.000657 AC: 100AN: 152178Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
100
AN:
152178
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000207 AC: 52AN: 250964Hom.: 0 AF XY: 0.000206 AC XY: 28AN XY: 135748
GnomAD3 exomes
AF:
AC:
52
AN:
250964
Hom.:
AF XY:
AC XY:
28
AN XY:
135748
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000718 AC: 105AN: 1461820Hom.: 0 Cov.: 32 AF XY: 0.0000729 AC XY: 53AN XY: 727214
GnomAD4 exome
AF:
AC:
105
AN:
1461820
Hom.:
Cov.:
32
AF XY:
AC XY:
53
AN XY:
727214
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000650 AC: 99AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.000698 AC XY: 52AN XY: 74482
GnomAD4 genome
AF:
AC:
99
AN:
152296
Hom.:
Cov.:
32
AF XY:
AC XY:
52
AN XY:
74482
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
7
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
27
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:7Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Lysosomal acid lipase deficiency Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | May 10, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Feb 09, 2017 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 05, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 13, 2024 | BS1 - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 01, 2023 | Variant summary: LIPA c.683T>C (p.Phe228Ser) results in a non-conservative amino acid change located in the alpha/beta hydrolase fold-1 domain (IPR000073) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00021 in 250964 control chromosomes, predominantly at a frequency of 0.0025 within the African or African-American subpopulation in the gnomAD database. This frequency is approximately equal to the estimated maximal expected allele frequency for a pathogenic variant in LIPA causing Lysosomal Acid Lipase Deficiency (0.00021 vs 0.0027), suggesting it could be a benign polymorphism found predominately in individuals of African ancestry. c.683T>C has been reported in the literature in the heterozygous state in two individuals affected with familial hypercholesterolemia, but no diagnosis of Lysosomal Acid Lipase Deficiency (Sjouke_2016). This report does not provide unequivocal conclusions about association of the variant with Lysosomal Acid Lipase Deficiency. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 32041611, 27423329). Four submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Three submitters classified the variant as uncertain significance and one classified it as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
LIPA-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 09, 2024 | The LIPA c.683T>C variant is predicted to result in the amino acid substitution p.Phe228Ser. This variant has been reported in two individuals with hypercholesterolaemia and in an individual from a cohort being studied for dyslipidemia (Table 2, Sjouke et al. 2016. PubMed ID: 27423329; Table S4, Dron et al. 2020. PubMed ID: 32041611). This variant is reported in 0.25% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 21, 2024 | The p.F228S variant (also known as c.683T>C), located in coding exon 6 of the LIPA gene, results from a T to C substitution at nucleotide position 683. The phenylalanine at codon 228 is replaced by serine, an amino acid with highly dissimilar properties. This variant has been reported in a familial hypercholesterolemia (FH) cohort (Sjouke B et al. Atherosclerosis, 2016 Aug;251:263-265). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. - |
Wolman disease Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T;.;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;T;T;T
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;.;.
PrimateAI
Benign
T
PROVEAN
Pathogenic
D;D;.;D
REVEL
Uncertain
Sift
Benign
T;T;.;T
Sift4G
Uncertain
T;D;T;.
Polyphen
P;D;.;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at